Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IMPAX Laboratories, Inc.�
23.35
-0.04 (-0.17%)
Real-time:   12:08PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.24 - 24.18
52 week 19.39 - 31.04
Open 23.51
Vol / Avg. 197,434.00/820,453.00
Mkt cap 1.64B
P/E 579.84
Div/yield     -
EPS 0.04
Shares 70.06M
Beta 1.06
Inst. own 81%
Aug 6, 2014
Q2 2014 Impax Laboratories Earnings Release - 9:30AM EDT - Add to calendar
Aug 6, 2014
Q2 2014 Impax Laboratories Inc Earnings Call - 8:30AM EDT - Add to calendar
Jun 12, 2014
Impax Laboratories Inc at Goldman Sachs Healthcare Conference
May 20, 2014
Impax Laboratories at UBS Global Healthcare Conference
May 15, 2014
Impax Laboratories at Bank of America Merrill Lynch Health Care Conference
May 13, 2014
Impax Laboratories Annual Meeting of Stockholders
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 5.41% 19.80%
Operating margin 6.93% 28.08%
EBITD margin - 11.76%
Return on average assets 2.60% 10.88%
Return on average equity 3.15% 13.49%
Employees 973 -
CDP Score - -

Address

30831 Huntwood Avenue
HAYWARD, CA 94544
United States - Map
+1-510-2406000 (Phone)
+1-510-4713200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Impax Laboratories Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established drug names. The Impax Division is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. In July 2014, Impax Laboratories Inc acquired from Actavis plc two generic products.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 46
Bio & Compensation  - Reuters
Carole S. Ben-Maimon M.D. President - Global Pharmaceuticals Division
Age: 55
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 55
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Larry Hsu Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Mary K. Pendergast JD., Director
Age: 63
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Allen Chao Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters